Stryker Introduces Synchfix EVT for Versatile Syndesmotic Stabilization

Stryker Unveils Synchfix EVT for Enhanced Syndesmotic Fixation

Stryker (SYK) has broadened its trauma product offerings with the introduction of Synchfix EVT, an advanced flexible syndesmotic fixation system. This new device is engineered to streamline surgical procedures and provide reliable ankle stabilization for patients suffering from syndesmotic injuries. Building on the foundation of the original Synchfix platform, Synchfix EVT incorporates design improvements that simplify its use and reduce the number of steps required during surgery compared to its predecessor.

According to company leadership, Synchfix EVT supports Stryker’s commitment to boosting surgical efficiency for foot and ankle specialists, while prioritizing patient safety and outcomes. The device is a result of ongoing investment in innovative soft tissue solutions aimed at optimizing surgical workflows. Feedback from surgeons played a key role in refining both the device and the associated procedure, resulting in practical enhancements.

Stryker plans to demonstrate the capabilities of Synchfix EVT through hands-on sessions at the American College of Foot and Ankle Surgeons Annual Meeting.

Impact on SYK Stock Performance

After the announcement, Stryker’s shares closed down 0.9%. Over the past half-year, the company’s stock has slipped 2.5%, while the broader medical-dental supplies industry declined by 12.3%. In contrast, the S&P 500 index saw an 8.1% gain during the same period.

Looking ahead, the launch of Synchfix EVT is expected to strengthen Stryker’s Foot & Ankle portfolio, expanding its reach in the sports medicine and trauma segments. The device’s approval for adolescent use increases the potential patient pool and offers a first-mover advantage. Its single-use, knotless, and sterile design is intended to improve operating room efficiency. Showcasing the product at a major industry event should support early adoption. Overall, this launch highlights Stryker’s ongoing innovation and could drive long-term growth in its trauma division.

Stryker’s current market capitalization stands at $147.23 billion.

Image Source: Zacks Investment Research

Details About Synchfix EVT

Synchfix EVT is an integrated system that combines suture tensioning and implant tools into one device. Its ergonomic handle allows for precise, single-handed operation during surgery. The system features a low-profile titanium medial implant, designed to enhance ease of use.

This device is intended for stabilizing soft tissue and bone injuries related to ankle syndesmosis disruptions, with or without accompanying fractures. It is compatible with standard fracture hardware for Weber B, Weber C, and Maisonneuve fracture types, and is suitable for both adults and adolescents.

Notably, Synchfix EVT is the first flexible syndesmotic fixation device cleared for adolescent patients, broadening its clinical applications and addressing a previously underserved group. The system has been honored with the Red Dot Design Award for its innovative all-in-one approach, which improves both fixation and procedural efficiency compared to earlier models.

Industry Outlook

the global trauma and extremities devices market is projected to reach $16.55 billion by 2026, with an expected compound annual growth rate (CAGR) of 5.2% through 2034.

Market expansion is being driven by a rising incidence of orthopedic injuries and disorders, as well as advancements in minimally invasive surgical techniques such as intramedullary nails and locking plate systems, which promote faster recovery and minimize soft tissue damage.

Additional Stryker Product Launches

Stryker has also introduced the T2 Alpha Humerus Nailing System, further enhancing its trauma portfolio. This system, based on SOMA technology, is designed to improve anatomical alignment and fixation for complex humeral fractures, while integrating with the T2 Alpha platform to streamline workflows and standardize hospital procedures.

Additionally, Stryker announced a limited release of the Mako RPS (Robotic Power System) for Total Knee procedures. This handheld robotic solution merges Stryker’s robotics expertise with its established power tool technologies, expanding the Mako platform into new territory. Compatible with the Triathlon Total Knee System, Mako RPS offers intraoperative planning and a robotically guided saw with active adjustment technology, aligning cuts with the surgical plan and integrating smoothly with existing systems like the Q Guidance System.

Stryker Corporation Stock Information

• Stryker Corporation price
• Stryker Corporation Quote

Stryker’s Zacks Rank and Notable Peers

Currently, Stryker holds a Zacks Rank #3 (Hold).

Other medical sector stocks with higher Zacks rankings include:

• Intuitive Surgical (ISRG): Zacks Rank #1 (Strong Buy). Reported Q4 2025 adjusted EPS of $2.53, exceeding estimates by 12.4%, with revenues of $2.87 billion, 4.7% above expectations. The company’s estimated long-term earnings growth rate is 15.7%, outpacing the industry’s 13.5% rise. It has surpassed earnings estimates in the last four quarters, with an average surprise of 13.2%.
• GE HealthCare Technologies (GEHC): Zacks Rank #2 (Buy). Posted Q4 2025 adjusted EPS of $1.44, 0.7% above consensus, and revenues of $5.7 billion, beating estimates by 1.9%. The company’s projected long-term earnings growth rate is 9.1%, compared to the industry’s 12.8%. It has exceeded earnings estimates in the last four quarters, with an average surprise of 7.5%.
• Veracyte (VCYT): Zacks Rank #2. Reported Q3 2025 adjusted EPS of $0.51, surpassing estimates by 59.4%, and revenues of $131.8 million, 5.5% above expectations. The company’s estimated earnings recession rate for 2026 is 3%, compared to the industry’s 16.8% rise. Veracyte has beaten earnings estimates in the last four quarters, with an average surprise of 45.1%.

For a full list of Zacks #1 Rank stocks, click here.

Top Semiconductor Stock Highlighted by Zacks

A lesser-known company specializing in semiconductor products not produced by industry giants like NVIDIA is poised for significant growth as the market enters a new phase. With robust earnings and a growing customer base, this company is well positioned to capitalize on the expanding demand for Artificial Intelligence, Machine Learning, and the Internet of Things. Global semiconductor manufacturing is expected to surge from $452 billion in 2021 to $971 billion by 2028.

Get More Investment Insights

Looking for the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days.

• Stryker Corporation (SYK): Free Stock Analysis Report
• Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
• Veracyte, Inc. (VCYT): Free Stock Analysis Report
• GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

Original article published by Zacks Investment Research.

For more information, visit Zacks Investment Research.